Skip to main content

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).

Publication ,  Journal Article
Smith, SM; Schöder, H; Johnson, JL; Jung, S-H; Bartlett, NL; Cheson, BD; Alliance for Clinical Trials in Oncology,
Published in: Leuk Lymphoma
July 2013

Relapsed Hodgkin lymphoma remains a clinical challenge, with few non-cytotoxic treatment options. CD80 is a surface antigen that normally functions as a co-stimulatory molecule but is aberrantly and uniformly expressed on Reed-Sternberg cells. Galiximab is a primatized monoclonal antibody against CD80, with a favorable toxicity profile demonstrated in other lymphomas. Cancer and Leukemia Group B (CALGB) 50602 (Alliance) tested single-agent galiximab in a highly refractory group of patients with Hodgkin lymphoma (median 3 prior regimens, 83% failing after prior stem cell transplant) to determine the efficacy. The overall response rate was 10.3% and the median progression-free survival was 1.6 months. Galiximab was well-tolerated, with minimal grade 3 or 4 toxicities. Despite this preclinical rationale, single-agent galiximab had limited activity in heavily pretreated Hodgkin lymphoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

July 2013

Volume

54

Issue

7

Start / End Page

1405 / 1410

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Recurrence
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Hodgkin Disease
  • Hematopoietic Stem Cell Transplantation
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Smith, S. M., Schöder, H., Johnson, J. L., Jung, S.-H., Bartlett, N. L., Cheson, B. D., & Alliance for Clinical Trials in Oncology, . (2013). The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma, 54(7), 1405–1410. https://doi.org/10.3109/10428194.2012.744453
Smith, Sonali M., Heiko Schöder, Jeffrey L. Johnson, Sin-Ho Jung, Nancy L. Bartlett, Bruce D. Cheson, and Bruce D. Alliance for Clinical Trials in Oncology. “The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).Leuk Lymphoma 54, no. 7 (July 2013): 1405–10. https://doi.org/10.3109/10428194.2012.744453.
Smith, Sonali M., et al. “The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).Leuk Lymphoma, vol. 54, no. 7, July 2013, pp. 1405–10. Pubmed, doi:10.3109/10428194.2012.744453.
Smith SM, Schöder H, Johnson JL, Jung S-H, Bartlett NL, Cheson BD, Alliance for Clinical Trials in Oncology. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013 Jul;54(7):1405–1410.

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

July 2013

Volume

54

Issue

7

Start / End Page

1405 / 1410

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Recurrence
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Hodgkin Disease
  • Hematopoietic Stem Cell Transplantation
  • Female